RT Journal Article
SR Electronic
T1 Hearing screening beyond the clinic: Childhood cancer survivors’ perceptions of a novel hearing screening program
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.02.27.25322837
DO 10.1101/2025.02.27.25322837
A1 Jörger, Philippa
A1 Nigg, Carina
A1 Schreck, Leonie
A1 Schindera, Christina
A1 Fessler, Katharina
A1 Waespe, Nicolas
A1 Tomášiková, Zuzana
A1 Ansari, Marc
A1 Frahsa, Annika
A1 Kuehni, Claudia
YR 2025
UL http://medrxiv.org/content/early/2025/03/03/2025.02.27.25322837.abstract
AB Purpose Childhood cancer survivors (CCS) are at risk for late effects including hearing loss due to ototoxic treatments. It is crucial to detect late effects like hearing loss early, but many adult CCS do not attend recommended follow-up care due to barriers such as accessibility and emotional concerns associated with revisiting medical facilities. To address those barriers, the HEAR-study piloted a new hearing screening program leveraging the extensive network of hearing aid shops across Switzerland. This study explored perceptions of CCS about this novel screening program.Methods We conducted semistructured interviews with 29 participants who completed a hearing test at a hearing aid shop as part of the HEAR-study. We used thematic analysis of interview transcripts, supported by MAXQDA for data analysis.Results Thematic analysis revealed two key themes: First, participants appreciated the program’s practicality but noted concerns about the effort of an additional appointment. Second, participants valued the personal and approachable environment in hearing aid shops, but some participants preferred hearing tests as part of an appointment with physicians, valuing immediate advice and contextual knowledge, especially in case hearing loss was found.Conclusions From the perspectives of CCS, this screening program shows promise as a practicable, accessible way to evaluate hearing after childhood cancer. Further evaluation from the perspectives of health care providers is needed to comprehensibly assess its feasibility.Implications for CCS For survivors prioritizing convenience or fearing medical institutions, follow-up screenings at accessible, community-based locations like hearing aid shops could provide a practical approach to monitoring hearing.Competing Interest StatementAuthors PJ, CN, LS, KF, ZT, AF and CK have no relevant financial or nonfinancial interests to disclose. NW reports a relationship with Swedish Orphan Biovitrum AB that includes advisory board membership, consulting, and travel reimbursement and a relationship with Novartis that includes advisory board membership. CS reports a relationship to Swedish Orphan Biovitrum AB that includes travel reimbursement. MA reports a relationship with Jazz Pharmaceutical and Novo Nordisk that includes travel reimbursement. None of these relationships has any association with the current study.Clinical TrialNCT06036407Funding StatementThis work was financially supported by the Swiss Cancer League and Swiss Cancer Research (grant number HSR-4951-11-2019, KLS/KFS-5711-01-2022, and KFS-5302-02-2021). The CANSEARCH foundation, Kinderkrebs Schweiz Foundation, and Zoe4Life Foundation supported NW.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of the Canton of Bern gave ethical approval for this work. (166/2014; 2021-01624)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets generated or analyzed during this study are stored on secured servers of the Institute of Social and Preventive Medicine at the University of Bern. Individual-level, fully anonymized, sensitive data can only be made available for researchers who fulfil the respective legal requirements.